Literature DB >> 6438504

Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction.

K P Rentrop, F Feit, H Blanke, P Stecy, R Schneider, M Rey, S Horowitz, M Goldman, K Karsch, H Meilman.   

Abstract

We randomly assigned patients with a clinical diagnosis of acute myocardial infarction to one of four treatment groups: intracoronary streptokinase, intracoronary nitroglycerin, intracoronary streptokinase and intracoronary nitroglycerin, or conventional therapy without initial angiography. Of 124 patients 122 sustained acute myocardial infarction. Initial angiography revealed total occlusion of the coronary artery responsible for infarction in 67 per cent (61 of 91). Acute recanalization occurred in 74 per cent (32 of 43) of patients receiving streptokinase but in only 6 per cent (1 of 18) of patients treated with nitroglycerin alone (P less than 0.01). At angiography of all four groups on Day 10 to 14 the vessel responsible for acute myocardial infarction was patent in 77 per cent (71 of 92) of patients; there was no difference among groups, indicating gradual, endogenous thrombolysis in patients not treated with streptokinase. Patients with subtotal obstruction initially had significant improvement in left ventricular function, significantly lower peak creatine kinase levels, and a trend toward lower mortality than patients with total occlusion initially. Mortality at six months in patients receiving streptokinase (21 per cent, 13 of 62) did not differ significantly from that in patients not treated with streptokinase (10 per cent, 6 of 61). Additional studies will be necessary to assess treatment effects in the angiographic subsets identified by this trial.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438504     DOI: 10.1056/NEJM198412063112301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

Review 1.  Emergency management of acute myocardial infarction.

Authors:  S Maxwell
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Treating myocardial infarction in the post-GUSTO era. A US perspective.

Authors:  D B Mark
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

3.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

4.  Myocardial protection during surgical intervention for treatment of acute myocardial infarction.

Authors:  F Beyersdorf; G D Buckberg
Journal:  Tex Heart Inst J       Date:  1992

Review 5.  Nuclear medicine at the crossroads.

Authors:  H W Strauss
Journal:  Eur J Nucl Med       Date:  1996-06

6.  Cineangiographic evaluation of changes in regional left ventricular wall motion after acute myocardial infarction.

Authors:  A Ohno; M Fujita; S Sasayama; K Yamanishi; O Sakai; M Eziri
Journal:  Heart Vessels       Date:  1987       Impact factor: 2.037

Review 7.  The Jeremiah Metzger lecture. Thrombolysis and dilatation in coronary occlusion.

Authors:  R S Ross
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

8.  [Successful treatment of superior mesenteric artery thrombosis with local high-dose urokinase therapy].

Authors:  M Köhler; B Kramann; P Hellstern; W Fess; P Walter; H Woerner; R Kiehl; E Wenzel
Journal:  Klin Wochenschr       Date:  1985-08-01

9.  Long term improvement in global left ventricular function after early thrombolytic treatment in acute myocardial infarction. Report of a randomised multicentre trial of intracoronary streptokinase in acute myocardial infarction.

Authors:  J C Res; M L Simoons; E E van der Wall; M J van Eenige; F Vermeer; F W Verheugt; W Wijns; S Braat; W J Remme; P W Serruys
Journal:  Br Heart J       Date:  1986-11

10.  Intracoronary thrombolytic treatment: another hazard.

Authors:  H Singh; M S Ruttley
Journal:  Br Heart J       Date:  1986-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.